Scatter plot for the significant Mendelian randomization (MR) association (P < 0.05) between mediators and anti-H. pylori IgG seropositivity. by Jing Wang (6206297)

Mean values and 95% confidence intervals for recovery time, Average NN Interval (AVNN); Standard Deviation of NN Intervals (SDNN), Low Frequency/ High Frequency Ratio (LF/HF); and... by Robert Trybulski (10998702)

Boxplot comparing Ct values for HD in flies and clothes. by Philippe Ndzomo (17706039)

Global Land Use Change Impacts on Soil Nitrogen Availability and Environmental Losses by Jing Wang (6206297)

S1 Data. Bibliometric analysis. S2 Data. Estrogen level analysis. S3 Data. MicroCT quantification. S4 Data. Markers of bone metabolism. by Yan She (8639796)

Skin marks is the S1 Fig title. by Mercedes Soto-González (20422078)

Details of the GWAS data in this study. by Jing Wang (6206297)

“…</p><p>Results</p><p>This study shows that increases of anti-H. pylori IgG seropositivity was significantly associated with an increased risk of CHD (OR=1.003, 95% CI:1.0001.006, P = 0.048) and increases in peak insulin response (β = 0.214, 95% CI: 0.025–0.403, P = 0.026), decrease in total free cholesterol levels (β = ‒0.031, 95% CI: ‒0.061 to ‒0.000, P = 0.045), decreased waist circumference (β = ‒0.073, 95% CI: ‒0.138 to ‒0.008, P = 0.027) and waist-to-hip ratio (β = ‒0.069, 95% CI: ‒0.136 to ‒0.002, P = 0.044). …”

Results data from this Mendelian randomization study. by Jing Wang (6206297)

Mendelian randomization analyses for the relevance of anti-H. pylori IgG seropositivity with risk of CHD. by Jing Wang (6206297)

Associations of anti-H. pylori IgG seropositivity with mediators. by Jing Wang (6206297)

Forest plot for the significant MR association between four mediators and anti-H. pylori IgG seropositivity. by Jing Wang (6206297)

Mendelian randomization analysis of the effect of anti-H. pylori IgG seropositivity on coronary heart disease (CHD). by Jing Wang (6206297)

Three essential assumptions of the Mendelian randomization study. by Jing Wang (6206297)

Flowchart of patient selection in this study. by Kazuyoshi Ohkawa (836847)

“…In addition, the mean aspartate aminotransferase-to-platelet ratio index (APRI) decreased during letrozole treatment; the values at 18 and 24 months were significantly lower than those at baseline (p = 0.024 and p = 0.026). …”

S1 Data - by Kazuyoshi Ohkawa (836847)

“…In addition, the mean aspartate aminotransferase-to-platelet ratio index (APRI) decreased during letrozole treatment; the values at 18 and 24 months were significantly lower than those at baseline (p = 0.024 and p = 0.026). …”

Clinical features and cancer treatment in patients with breast cancer receiving letrozole and anastrozole. by Kazuyoshi Ohkawa (836847)

Clinical course of patient no. by Kazuyoshi Ohkawa (836847)

Changes in the liver fibrosis-related markers in breast cancer patients with a FIB-4 index of >2.30 during letrozole treatment. by Kazuyoshi Ohkawa (836847)

Changes in the FIB-4 index in breast cancer patients with a FIB-4 index of ≥ 2.67 during letrozole and anastrozole treatment. by Kazuyoshi Ohkawa (836847)

Changes in the liver fibrosis-related markers in breast cancer patients with a FIB-4 index of >2.30 during anastrozole treatment. by Kazuyoshi Ohkawa (836847)